1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
261.96%
Cash & equivalents growing 261.96% while Drug Manufacturers - Specialty & Generic shows decline of -1.06%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
No Data
No Data available this quarter, please select a different quarter.
261.96%
Below half the Drug Manufacturers - Specialty & Generic median of -1.69% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
26.68%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
-10.75%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
41.47%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
114.11%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a potential liquidity edge if well allocated.
15.02%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.16%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
9053.30%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
9053.30%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.72%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
84.12%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 1.44%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
100.93%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 1.53%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-1.09%
Payables growth below half of Drug Manufacturers - Specialty & Generic median of 2.56%. Joel Greenblatt sees more conservative payables management vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.09%
Below half Drug Manufacturers - Specialty & Generic median of 1.14%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.09%
Below half Drug Manufacturers - Specialty & Generic median of 1.05%. Joel Greenblatt sees a much lower liability expansion vs. peers.
67.96%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
1.37%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
28.27%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
113.77%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 2.19%. Joel Greenblatt sees stronger equity growth vs. peers.
100.93%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 1.53%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-261.96%
Below half of Drug Manufacturers - Specialty & Generic median 1.88%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.